Navigation Links
Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company
Date:3/26/2009

EMERYVILLE, Calif., March 26 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) announced today that it has hired RBC Capital Markets as its exclusive financial advisor to assist in the evaluation of various options to enhance shareholder value, including a potential sale of the Company or its major assets.

"We have retained RBC Capital Markets to assist us in efficiently determining if there is a transaction more beneficial to our shareholders than a liquidation," stated William Fletcher, acting Chief Executive Officer. "We have a duty to our shareholders to maximize the value of NTI. We intend to proceed expeditiously in this process while continuing to wind-down operations, cut expenses and preserve cash. If our evaluation of strategic options does not result in a transaction that meets our objectives, NTI will act expeditiously to return as much cash as possible to our shareholders through a liquidation or other means."

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions and other serious unmet medical needs. The company recently terminated development of its most advanced product candidate, Viprinex(TM) (ancrod), which was studied in Phase 3 clinical trials as a potential new drug to treat acute ischemic stroke. NTI has recently chosen not to extend its early-stage research program for Alzheimer's disease beyond the first year of a collaborative agreement with the Buck Institute. NTI has rights to receive payments from an approved drug for Alzheimer's disease and an investigational drug which has recently completed a Phase 3 trial for brain swelling.

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including risks relating to our terminated clinical trials, our continuing contractual commitments, the outcome of our efforts to maximize value following the hiring of RBC Capital Markets as financial advisor, and levels of future operations and expenditures, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release and we undertake no obligation to update these forward-looking statements.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
2. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
3. Neurobiological Technologies Announces Suspension of Viprinex Development
4. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
5. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
6. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
7. Neurobiological Technologies Sets Date for First Quarter Financial Results
8. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
9. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
10. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
11. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 ... company reports the Company,s CEO  was featured in ... Accelerators Enter When VCs Fear To Tread: ... Leader magazine is an essential business ... everything from emerging biotechs to Big Pharmas. Their ...
(Date:4/28/2016)... ... April 28, 2016 , ... As part ... top industry experts, and expanding its LATAM network and logistics capabilities. Enhancements ... to manage their clinical trial projects. , The expansion will provide unmatched clinical ...
(Date:4/27/2016)... ... ... Shimadzu Scientific Instruments (SSI) will be showcasing a broad ... Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis products for potency, moisture, ... booth 1021 to learn how Shimadzu’s instruments can help improve QA/QC testing, peak ...
(Date:4/27/2016)... British Columbia , April 27, 2016 /PRNewswire/ ... oder "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( ... im Anschluss an ihre Pressemitteilung vom 13. August ... erhalten hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten ... 4.000.000 Kanadische Dollar zu bringen. Davon wurden 157.900.000 ...
Breaking Biology Technology:
(Date:3/15/2016)... 15, 2016 Yissum Research Development Company ... company of the Hebrew University, announced today the formation ... technology of various human biological indicators. Neteera Technologies has ... from private investors. ... detection of electromagnetic emissions from sweat ducts, enables reliable ...
(Date:3/14/2016)... , Allemagne, March 14, 2016 ... http://www.apimages.com ) - --> - Renvoi : ... - --> --> ... solutions biométriques, fournit de nouveaux lecteurs d,empreintes digitales ... LF10 de DERMALOG sera utilisé pour produire des ...
(Date:3/11/2016)... PUNE, India , March 11, 2016 ... to a new market research report "Image Recognition Market ... by Application (Marketing and Advertising), by Deployment Type (On-Premises ... Global Forecast To 2022", published by MarketsandMarkets, the global ... in 2015 to USD 29.98 Billion by 2020, at ...
Breaking Biology News(10 mins):